Plavix, 15 Other Brands to Lose Premiums on Generic, Biosimilar Entries; Re-Pricing Could Deal Another Blow

Sanofi’s antiplatelet agent Plavix (clopidogrel) and 15 other brand-name drugs are expected to face a sharp price cut next April as they will be stripped of previously received price-maintenance premiums for on-patent drugs following the entries of their generic and...read more